BridgeBio Pharma Inc.

9 hours ago · fool.com

BridgeBio saw revenue climb by 193% year over year in the third quarter. The company's lead therapy is a heart drug, Attruby.

3 days ago · seekingalpha.com

BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript

3 days ago · marketbeat.com

BridgeBio Pharma NASDAQ: BBIO reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's commercialization of Beyonttra. The company also outlined plans for three potential U.S. product launches over the next seven months, subject to Food and Drug Administration decisions.

3 days ago · zacks.com

The headline numbers for BridgeBio Pharma (BBIO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

3 days ago · zacks.com

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.95 per share a year ago.

3 days ago · benzinga.com

BridgeBio Pharma (NASDAQ:BBIO) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.

3 days ago · globenewswire.com

- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 million, driven by increased revenue and a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, fully funding all three launches and expansion indications

11 days ago · globenewswire.com

PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its third quarter 2026 financial results and business update after the market closes on Thursday, October 29, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

13 days ago · zacks.com

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.

20 days ago · seekingalpha.com

BridgeBio Pharma maintains a "Strong Buy" rating, driven by robust revenue growth and multiple late-stage pipeline catalysts. The company delivered Q2 2026 net revenues of $243.7M, up from the prior year's $110.6M, outperforming despite competition. Three NDA submissions—BBP-418, oral infigratinib, and encaleret—are under Priority Review, with PDUFA dates spanning late 2026 to mid-2027.